Accesswire
14 Aug 2026, 10:45 UTC · 55m ago
CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Accesswire
14 Aug 2026, 10:45 UTC · 55m ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
CASI Pharmaceuticals was delisted from Nasdaq and now trades on the OTCQB market. — Delisting from a major exchange to the OTC market typically signals severe compliance or financial issues and drastically reduces institutional liquidity.
-0.80The company won a final arbitration award against Juventas totaling over RMB 100 million. — This provides a significant non-dilutive cash infusion for a company with relatively low cash reserves.
+0.60CASI raised $15 million through convertible note financing from a partnership controlled by its own Executive Chairman. — While providing necessary liquidity, the insider nature of the loan can be viewed as a sign of limited external appetite for the company's debt.
+0.40Continue reading
6 related stories
Search tags
The company dosed the first patient in its Phase 1/2 trial for CID-103 in renal allograft AMR in China. — Advancement into clinical dosing is a positive milestone for the lead pipeline candidate, reducing binary development risk.
+0.30First half 2026 revenues decreased 5.8% to $9.8 million due to a product transition from EVOMELA to MAFALAN. — A decline in top-line revenue is generally negative, though partially offset by a significant decrease in the cost of revenue.
-0.20Which stocks this story touches
Positive progress in clinical trials and a favorable arbitration award, though offset by a Nasdaq delisting and continued net losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
CNBC International TV
2h ago
